AstraZeneca seals $1.92 billion licensing deal with Hong Kong’s CSPC

AstraZeneca seals $1.92 billion licensing deal with Hong Kong’s CSPC
AstraZeneca seals $1.92 billion licensing deal with Hong Kong’s CSPC

AstraZeneca has inked a high-stakes deal with Hong Kong-listed pharmaceutical company CSPC to get into an exclusive license agreement that is worth over $1.92 billion!

On Monday, October 7, the British-Swedish pharmaceutical company announced that it has entered an exclusive partnership to boost the Anglo-Swedish drugmaker’s cardiovascular portfolio.

Along with this major milestone and royalty payment, the CSPC pharmaceutical Group Ltd. will also get an advance payment of $100 million as a part of the deal.

According to AstraZeneca, CSPC is going to develop “an early-stage, novel small molecule Lipoprotein (a) disruptor, which could offer benefits to patients with high levels of "bad cholesterol,” reported Reuters.

This deal will give AstraZeneca access to CSPC’s pre-clinical candidate small molecule, YS2302018, which is an oral Lp(a) disruptor. Lp(a), which is a form of low-density lipoprotein, helps in transporting cholesterol in the blood streams.

“The asset could help address the major risk factors driving chronic cardiovascular diseases, alone or in combination with other drugs, including AstraZeneca's oral small molecule PCSK9 inhibitor AZD0780,” said the company’s statement as per the outlet.

According to the Vice President and Head of AstraZeneca Sharon Barr, “This asset is an important addition to our cardiovascular pipeline and could help patients to more effectively manage their dyslipidaemia and related cardiometabolic diseases.”

Related
Read more : Health

Air pollution associated with common brain tumors, study

Air pollution associated with common brain tumors, study
Meningiomas are tumours that develop in the layers of tissue covering the brain and spinal cord

Malaria treatment breakthrough: First-ever treatment approved for newborns

Malaria treatment breakthrough: First-ever treatment approved for newborns
Malaria treatment gap closed after first drug approved for newborns and infants under 11 pounds

Breakthrough T1D 2025 and Mattel unveil first Barbie doll with type 1 diabetes

Breakthrough T1D 2025 and Mattel unveil first Barbie doll with type 1 diabetes
The Barbie doll consists of a CGM on her arm, a pink insulin pump, along with a handset with a CGM app to monitor her glucose levels

Legionnaires outbreak: 1 dead, 40 people sick in London, Ontario

Legionnaires outbreak: 1 dead, 40 people sick in London, Ontario
Legionnaires’ disease is a rare respiratory disease caused by Legionella bacteria that may lead to pneumonia

How obesity affect breast cancer risk in postmenopausal women?

How obesity affect breast cancer risk in postmenopausal women?
Development of type 2 diabetes did not appear to affect breast cancer risk related to BMI

New Covid strain takes over UK with unique symptoms

New Covid strain takes over UK with unique symptoms
Stratus consists of two strains, XFG and XFG.2, which constitute up to 30% of cases across the UK

THESE common meds do not cause inflammatory bowel disease, study

THESE common meds do not cause inflammatory bowel disease, study
Medicines including NSAIDs like aspirin and ibuprofen, ACE inhibitors, aren’t linked to a higher risk of microscopic colitis

Juice, smoothies and soft drinks can dehydrate you in hot weather, say experts

Juice, smoothies and soft drinks can dehydrate you in hot weather, say experts
Alcohol should also be avoided in hot weather as it causes the body to lose water which often leads to dehydration